MIKE Redmond, the chairman of global biotechnology company Abcam, will step down from the board after the company’s annual general meeting later this year, the firm announced yesterday.
Abcam, which was founded in 1998 and is a producer and distributor of high quality innovative protein research tools, has a catalogue of more than 130,000 products it ships to over 100 countries.
The Aim-listed company employs more than 700 people and is based at the Science Park in Cambridge. It also has offices in China, the US and Japan, and R&D and production facilities in the UK, US and China.
Redmond had been chairman for five years, and Abcam announced he would be succeeded as chairman by Murray Hennessy, who has served as non-executive director.